✦ LIBER ✦

Lamivudine therapy for spontaneously occurring severe acute exacerbation in chronic hepatitis B virus infection: a preliminary study

✍ Scribed by Akihito Tsubota; Yasuji Arase; Satoshi Saitoh; Masahiro Kobayashi; Yoshiyuki Suzuki; Fumitaka Suzuki; Kazuaki Chayama; Naoya Murashima; Kenji Ikeda; Mariko Kobayashi; Hiromitsu Kumada

Book ID: 119390267
Publisher: Nature Publishing Group
Year: 2001
Tongue: English
Weight: 206 KB
Volume: 96
Category: Article
ISSN: 0002-9270
DOI: 10.1016/s0002-9270(00)02352-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Acute Exacerbation of Chronic Hepatitis

Acute Exacerbation of Chronic Hepatitis B Virus Infection After Withdrawal of Lamivudine Therapy

✍ Pieter Honkoop; Robert A. de Man; Hubert G.M. Niesters; Pieter E. Zondervan; Sol 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 141 KB

A 7-year study of lamivudine therapy for

A 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in China

✍ Guang Bi YAO; Mei ZHU; Zhen Yu CUI; Bao En WANG; Ji Lu YAO; Ming De ZENG 📂 Article 📅 2009 🏛 Wiley (Blackwell Publishing) 🌐 English ⚖ 160 KB

Long-term prognosis by lamivudine monoth

Long-term prognosis by lamivudine monotherapy for severe acute exacerbation in chronic hepatitis B infection: emergence of YMDD motif mutant and risk of breakthrough hepatitis – an open-cohort study

✍ Norio Akuta; Akihito Tsubota; Fumitaka Suzuki; Yoshiyuki Suzuki; Tetsuya Hosaka; 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 125 KB

Severe acute exacerbation of liver disea

Severe acute exacerbation of liver disease may reduce or delay emergence of YMDD motif mutants in long-term lamivudine therapy for hepatitis B e antigen-positive chronic hepatitis B

✍ Akihito Tsubota; Yasuji Arase; Fumitaka Suzuki; Mariko Kobayashi; Marie Matsuda; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 98 KB

## Abstract The pretherapy factors that could influence the emergence of resistant hepatitis B virus (HBV) tyrosine‐methionine‐aspartate‐aspartate (YMDD) motif mutants against lamivudine are not fully known in prolonged lamivudine therapy for hepatitis B e antigen (HBeAg)‐positive chronic hepatitis